



Regulated by the FSA

## **Cytox Limited**

<b>Investee Company</b>	<b>Cytox Limited</b>
<b>Sector</b>	<b>Medical/Health</b>
<b>Location</b>	<b>Birmingham</b>
<b>Round of Financing</b>	<b>First Round</b>
<b>Midven Role</b>	<b>Lead Investor</b>
<b>Investment Manager</b>	<b>Roger Wood</b>
<b>Date of Initial AGF Investment</b>	<b>1 December 2006</b>
<b>Midven Funds Committed</b>	<b>£250,000</b>

### **BUSINESS DESCRIPTION**

Cytox is developing a diagnostic test and therapeutic cures for Alzheimer's Disease which is estimated to affect 15 million people worldwide. The company is a university spin-out based on groundbreaking academic research into the role of the cell cycle in neuro-degenerative diseases.

### **MIDVEN ADDED VALUE**

The total funding round of £650,000 was led by Midven with a £250,000 commitment from the Advantage Growth Fund. Midven led negotiations with the university and project managed the fund-raising to ensure all participants in the funding round were still committed at completion.

### **RECENT DEVELOPMENTS**

The Cytox board has been strengthened by the appointment of a CEO and highly experienced Chairman. The company has already established a dialogue with a number of pharmaceutical companies that recognise the value of Cytox's new approach to Alzheimer's Disease.



#### ***Roger Wood***

Comments that "The research carried out by Cytox is groundbreaking yet very simple to understand and provides a compelling new argument for the cause of Alzheimer's Disease. The number of people suffering from Alzheimer's represents a hugely valuable market opportunity."